Candel Therapeutics: Getting Closer, And Building Out More Paths (NASDAQ:CADL)
· seekingalpha.com
Candel Therapeutics, Inc. stays a Buy as CAN-2409 nears FDA submission in prostate cancer, backed by phase 3 data and strong cash runway. Click for a CADL update.
I am now a contributor to Total Pharma Tracker, where you can join me for discussions, get my follow-ups on ideas, and specifically request ideas to explore. It...